8-K//Current report
PAVmed Inc. 8-K
Accession 0001493152-25-029510
$PAVMCIK 0001624326operating
Filed
Dec 29, 7:00 PM ET
Accepted
Dec 30, 9:00 AM ET
Size
258.1 KB
Accession
0001493152-25-029510
Research Summary
AI-generated summary of this filing
PAVmed Inc. Announces 1-for-30 Reverse Stock Split to Pursue Nasdaq Compliance
What Happened
- PAVmed Inc. (PAVM) filed an 8‑K on December 30, 2025 disclosing that its board approved a 1‑for‑30 reverse stock split and a reduction in authorized common stock. The company filed a certificate of amendment on December 30, 2025 to make the reverse split and the reduction effective at 12:01 a.m. Eastern Time on January 2, 2026; shares will trade on a split‑adjusted basis at the market open that day.
- The stated reason for the reverse split is to regain compliance with Nasdaq’s $1.00 minimum bid-price requirement after Nasdaq notified the company on January 23, 2025 that its closing bid had been below $1 for the prior 30 business days; PAVmed had an initial 180‑day cure period (to July 22, 2025) and was afforded an additional period through January 19, 2026.
Key Details
- Reverse split ratio: 1-for-30 (approved by the board); Effective Time: Jan 2, 2026 at 12:01 a.m. ET; split‑adjusted trading begins at market open Jan 2, 2026.
- Authorized shares: reduced from 250,000,000 to 25,000,000 common shares (absolute reduction; increases authorized shares relative to outstanding shares).
- CUSIP and symbol: New CUSIP will be 70387R 502; trading symbol remains "PAVM."
- Fractional shares: no fractional shares will be issued — the company will issue one whole post‑split share to any holder who otherwise would have been entitled to a fractional share; no cash will be paid for fractions.
- Security adjustments: outstanding stock options will be divided by 30 and exercise prices multiplied by 30 (rounded per plan terms); convertible securities’ conversion prices will be multiplied by 30; shares reserved under equity plans will be proportionately adjusted.
- Additional disclosures: the 8‑K also furnished (not filed) information under Item 2.02 (results of operations/financial condition) and Item 7.01 (Regulation FD disclosure); a press release and the Certificate of Amendment were included as exhibits.
Why It Matters
- For holders, each pre‑split share will convert to 1/30 of a post‑split share (subject to the company’s rounding policy), so share counts in brokerage accounts will be reduced accordingly and per‑share market price should increase in proportion — the company expects this to help meet Nasdaq’s $1 minimum bid rule.
- No action is required for brokerage account holders; holders of paper certificates should follow the transfer agent instructions to exchange certificates.
- While the reverse split is intended to restore Nasdaq compliance, the filing expressly notes there is no assurance the action will succeed; investors should consider this corporate action when evaluating share count, per‑share price, and potential liquidity changes.
Documents
- 8-Kform8-k.htmPrimary
8-K
- EX-3.1ex3-1.htm
EX-3.1
- EX-99.1ex99-1.htm
EX-99.1
- EX-101.SCHpavm-20251230.xsd
XBRL SCHEMA FILE
- EX-101.LABpavm-20251230_lab.xml
XBRL LABEL FILE
- EX-101.PREpavm-20251230_pre.xml
XBRL PRESENTATION FILE
- XMLR1.htm
IDEA: XBRL DOCUMENT
- XMLShow.js
IDEA: XBRL DOCUMENT
- XMLreport.css
IDEA: XBRL DOCUMENT
- XMLFilingSummary.xml
IDEA: XBRL DOCUMENT
- JSONMetaLinks.json
IDEA: XBRL DOCUMENT
- ZIP0001493152-25-029510-xbrl.zip
IDEA: XBRL DOCUMENT
- XMLform8-k_htm.xml
IDEA: XBRL DOCUMENT
Issuer
PAVmed Inc.
CIK 0001624326
Entity typeoperating
IncorporatedDE
Related Parties
1- filerCIK 0001624326
Filing Metadata
- Form type
- 8-K
- Filed
- Dec 29, 7:00 PM ET
- Accepted
- Dec 30, 9:00 AM ET
- Size
- 258.1 KB